WASHINGTON — A widely prescribed class of blood pressure medications may activate brown adipose tissue, a type of fat associated with protection against cardiovascular disease and Type 2 diabetes, according to a large NIH-funded study published Oct. 14.
The retrospective study, funded by the National Institute of Diabetes and Digestive and Kidney Diseases, found that angiotensin blockers such as losartan appear to stimulate brown fat activity in patients taking the medications, the National Institutes of Health said. Brown fat burns calories to generate heat and has been linked to improved metabolic health.
Losartan and similar angiotensin receptor blockers are among the most prescribed drug classes in the United States, with tens of millions of patients taking them daily to manage high blood pressure. If the findings are confirmed by prospective clinical trials, they could reshape understanding of how these medications work and open new avenues for treating metabolic disease.
The study was retrospective in design, meaning researchers analyzed existing patient data rather than conducting a new clinical trial. The findings are associative, showing a correlation between angiotensin blocker use and brown fat activation, but do not establish a causal relationship, the researchers noted.
Brown fat activation has previously been shown to be associated with protection against cardiovascular disease, Type 2 diabetes, and certain psychiatric conditions, according to NIH. Unlike white fat, which stores excess calories, brown fat actively metabolizes energy.
Further research, including prospective clinical trials, would be needed to confirm the association and determine whether brown fat activation is a meaningful mechanism of benefit in patients taking angiotensin blockers.